A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of CST-103 co-administered with CST-107 in 4 subject populations with Neurodegenerative Disorders.
Epistemonikos ID: 02c5d6ea447e7acfb814c8cd905aa781903b3c80
First added on: May 08, 2024